# Status

- Updated: 2026-09-03 (Asia/Taipei)
- Current Wave: `4 INDEPENDENT AUDIT — complete`
- **Current/Final Gate: `READY_WITH_EXTERNAL_BLOCKER`** (Decision 2026-09-03-17). Independent audit returned research-quality verdict `PASS_WITH_MINOR_ISSUES`; both findings (untraceable dose-stratified AE figure, incomplete OPTION-DM N) were fixed directly in `40_SYNTHESIS/`. **This run is NOT marked FINAL/PASS** — per explicit Human PI instruction, the LlamaParse network blocker (Decision 2026-09-03-15) remains open and is not waived. All research/synthesis/audit work not dependent on that blocker is complete.

## Completed

- Runbook reviewed.
- Target Mac mini/Tailscale identity verified.
- Claude Code authentication verified.
- Public GitHub output repository verified empty at start.
- Research Charter, ownership, source policy, and sponsor-bias guardrail initialized.
- Existing global MCP names inventoried; no credential copied into the repository.
- `academic-research-agents` implementation inspected and classified as architecture-only because core literature/PDF methods contain placeholders.
- Cross-session health check PASSED: all four persistent peers (`dpnp-source-provenance`, `dpnp-guideline-diagnosis`, `dpnp-trials-comparative`, `dpnp-pregabalin-safety`) located via `ListAgents` and confirmed READY. See `90_CROSS-SESSION-LOG/2026-09-03_STARTUP.md`.
- Wave 1 dispatched to and completed by `dpnp-source-provenance`: both MedNote pages captured (`10_SOURCES/MEDNOTE_CAPTURE.md`), source/search register built (`10_SOURCES/SOURCE_REGISTER.md`) covering ADA 2026 Ch.12, AAN 2022 update, 4 trial/SR-MA leads, Toronto Consensus lead; full-text ledger opened (`10_SOURCES/FULLTEXT_LEDGER.md`); `02_SOURCE-INVENTORY.md` updated with a preserved "not yet accepted" framing. No PDFs downloaded/parsed, no Sci-Hub/paywall bypass, no credentials committed.
- Gate 1 declared `READY_WITH_PENDING_ITEMS` (Decision 2026-09-03-05) — sufficient lead coverage to unblock Wave 2 deep verification; real gaps remain (see Open Questions).
- Wave 2 dispatched to `dpnp-guideline-diagnosis`, `dpnp-trials-comparative`, `dpnp-pregabalin-safety`.

## Completed (Wave 2 — all three specialists reported and accepted)

- `dpnp-trials-comparative`: Wave 2 evidence table complete (`20_EVIDENCE/trials-comparative/01_EVIDENCE-TABLE.md`) — T1 Freeman 2008, T2 Frontiers 2026 combo SR-MA, T3 Soliman/NeuPSIG 2025, T4 Mallick-Searle 2024 (narrative review), T5 COMBO-DN, T6 OPTION-DM all `ACCESS_VERIFIED` at primary record. Key counter-bias findings recorded (Decision 2026-09-03-06): α2δ-ligand class NNT ranks numerically worst of the three first-line classes per Soliman/NeuPSIG 2025; COMBO-DN found no significant combination-vs-monotherapy superiority; OPTION-DM found no pregabalin-pathway superiority over amitriptyline/duloxetine pathways.
- `dpnp-guideline-diagnosis`: Wave 2 claim table complete (`20_EVIDENCE/guidelines-diagnosis/01_CLAIM-TABLE.md`) — ADA 2026 Ch.12, AAN 2022 (+ AAN 2011 confirmed retired), Toronto Consensus 2010, and Atmaca 2024 (EXPERT INTERPRETATION, not a formal successor consensus) all `ACCESS_VERIFIED`. Independently corroborating counter-bias finding recorded (Decision 2026-09-03-08): current operative guidelines grade the drug class, not pregabalin specifically; only the retired 2011 AAN guideline gave pregabalin a drug-specific Level A.
- `dpnp-pregabalin-safety`: Wave 2 label verification complete (Decision 2026-09-03-09) — FDA label (Rev. 04/2025) and TFDA-stamped Taiwan insert both `ACCESS_VERIFIED`, numerically concordant on dosing/renal-adjustment/AE tables. All dispatched safety topics covered with locators. Two open items flagged, not guessed: Taiwan controlled-drug schedule unresolved; HLA-B*1502 mention identified as a likely template artifact and excluded from use.
- Wave 2 dispatch (task #3) is now complete for all three specialists.

## Completed (Challenge Round / Gate 2)

- All three Wave 2 specialists completed the adversarial challenge round. `dpnp-trials-comparative` produced four synthesis-phrasing guardrails against both overselling and over-correcting (Decision 2026-09-03-10), plus a targeted falls/fracture search (population-mismatched leads, routed to pregabalin-safety). `dpnp-guideline-diagnosis` found and transparently corrected a real extraction-tool locator error (Rec-number mislabeling, no clinical content changed — Decision 2026-09-03-11). `dpnp-pregabalin-safety` produced anti-downplaying/anti-overstating guardrail sentences plus a compounded-risk callout and a documentation-depth-asymmetry guardrail (Decision 2026-09-03-12).
- **Gate 2 declared `READY_WITH_PENDING_ITEMS`** (Decision 2026-09-03-13). Wave 3 (Director synthesis) now authorized to begin.

## Completed (Wave 3)

- Both required synthesis deliverables written: `40_SYNTHESIS/DPNP_Pregabalin_Moderator_Brief_zh-TW.md`, `40_SYNTHESIS/DPNP_10_Insightful_QA_zh-TW.md`. Gate 3 self-check passed (no MEDNOTE leakage, no unsupported reversal-of-nerve-damage language, numeric tokens consistent across both files and the merged evidence tables).

## Completed (Wave 4 — Independent Audit)

- Independent read-only auditor (temporary, no write access beyond `99_FINAL-QA.md`) completed full review: numbers, methods/evidence (all 6 mandated sponsor-bias checks passed with zero exceptions), writing, and provenance (8/8 spot-checked DOIs/PMIDs resolved correctly via Europe PMC, including the load-bearing AAN 2011 `[RETIRED]` tag). Research-quality verdict: `PASS_WITH_MINOR_ISSUES`.
- Director accepted the report and fixed both findings directly (Decision 2026-09-03-17): removed an untraceable dose-stratified AE figure from the Brief (replaced with the already-verified All-PGB figures plus a disclosure note, not silently dropped) and corrected an incomplete OPTION-DM sample-size statement in both synthesis files.
- A second read-only Claude CLI branch review after integration identified documentation/compliance issues not covered by the first audit. All high-confidence findings were corrected in Decision 2026-09-03-18: AAN restricted-source recommendation text was converted to concise paraphrase; the correct FDA 04/2025 PDF was downloaded/checksummed and designated as the future LlamaParse target; unsupported dose-stratified AE figures were removed from the evidence summary; the QA's full OPTION-DM N funnel and a standalone-audience cross-reference were corrected. A Human-PI-authorized attempt on the correct FDA 04/2025 PDF then returned `ConnectTimeout`, so the blocker remains. See `98_CLAUDE-REVIEW.md`.

## Gate history (all gates this run)

- Gate 1: `READY_WITH_PENDING_ITEMS` (Decision 2026-09-03-05).
- Gate 2: `READY_WITH_PENDING_ITEMS` (Decision 2026-09-03-13).
- Gate 3: `READY_FOR_AUDIT` (Decision 2026-09-03-16).
- **Final Gate: `READY_WITH_EXTERNAL_BLOCKER`** (Decisions 2026-09-03-17/-18) — research-quality findings are fully addressed; the run is deliberately NOT marked `FINAL`/plain `PASS` because the LlamaParse network blocker remains open. To close: restore network egress to `api.cloud.llamaindex.ai` and retry the current FDA PDF, or have the Human PI explicitly waive the requirement.

## Residual blocker (tracked separately from research gates)

- **LlamaParse network block**: five attempts have failed—four against the superseded 06/2020 DailyMed PDF, then one Human-PI-authorized attempt against the correct FDA 04/2025 PDF—with `WriteTimeout` once and `ConnectTimeout` otherwise. A zero-payload request to `api.cloud.llamaindex.ai` also stalls while other hosts work, confirming an environment-level egress problem rather than a file problem. No credentials were exposed. Remediation: restore network egress to `api.cloud.llamaindex.ai`, then retry `fulltext-local/LYRICA_pregabalin_FDA_2025_Ref5578761.pdf` (SHA-256 in `10_SOURCES/FULLTEXT_LEDGER.md`) without a new download. Interim mitigation: the current label's substantive content is already captured with section/page locators in `20_EVIDENCE/pregabalin-safety/LABELING_FDA.md` and used in `40_SYNTHESIS/`.

## Blockers

- **One open blocker, external to this research team**: the LlamaParse network egress issue (Decision 2026-09-03-15/-18), requiring Human PI/operator action. The correct FDA 04/2025 file has already been tried once and failed with `ConnectTimeout`; further attempts are not useful until connectivity changes. Everything else is non-blocking: several `NEEDS_SOURCE`/`NEEDS_EVIDENCE`/`NEEDS_FULLTEXT` items remain open (see `04_OPEN-QUESTIONS.md`) but are disclosed, not guessed. No claim may cite MEDNOTE-002's numeric figures (NNT/NNH/discontinuation) until independently sourced to a primary study.
